ICD-10 Coding for Anastrozole in Men on Testosterone Therapy
Use ICD-10 code E29.1 (Testicular hypofunction) as the primary diagnosis when ordering anastrozole for men receiving testosterone therapy who develop elevated estradiol levels.
Rationale for Code Selection
The appropriate ICD-10 code must reflect the underlying condition being treated—testosterone deficiency/hypogonadism—rather than the elevated estradiol itself, which is a consequence of testosterone therapy 1, 2.
Primary Diagnosis Options
E29.1 (Testicular hypofunction): This code encompasses male hypogonadism and testosterone deficiency, which is the fundamental condition requiring testosterone therapy 1, 2. This remains the appropriate primary diagnosis even when managing treatment-related complications like elevated estradiol.
E28.0 (Estrogen excess): While this code exists, it is primarily used for female conditions and is not the standard approach for men on testosterone therapy experiencing aromatization 3.
Clinical Context for Anastrozole Use
Anastrozole is prescribed off-label in men on testosterone therapy when estradiol levels become elevated through aromatization 3. The typical indications include:
- Estradiol >60 pg/mL regardless of symptoms, or
- Estradiol 40-60 pg/mL with subjective symptoms (gynecomastia, emotional lability, sexual dysfunction) 3
Approximately 3% of men on testosterone therapy require aromatase inhibitor treatment, with anastrozole 0.5 mg three times weekly being the standard regimen 3.
Supporting Documentation Requirements
When submitting claims, ensure documentation includes:
- Confirmed testosterone deficiency with total testosterone <300 ng/dL on two separate early morning measurements 2
- Symptoms and signs of hypogonadism that prompted testosterone therapy 1, 2
- Elevated estradiol levels while on testosterone therapy (specify the actual value) 3
- Current testosterone therapy regimen (topical, intramuscular, or other formulation) 1, 3
Common Pitfalls to Avoid
Do not use codes for breast cancer or female conditions (the primary FDA-approved indication for anastrozole), as this will result in claim denials for male patients 4. The drug label specifically addresses use in postmenopausal women with breast cancer, but off-label use in men with testosterone therapy-related estradiol elevation is well-established in clinical practice 3.
Avoid using symptom-only codes (such as R62.0 for gynecomastia alone) as the primary diagnosis, as these do not adequately justify the underlying need for both testosterone therapy and aromatase inhibition 1, 2.
Treatment Monitoring Justification
The E29.1 code also supports necessary follow-up laboratory monitoring, which should include 3: